Lindahl advises Corline Biomedical AB on directed share issue
Lindahl is acting as legal adviser to Corline Biomedical AB (publ) in connection with a directed share issue amounting to approximately SEK 23 million.
Through the share issue, Corline Biomedical will receive approximately SEK 23 million before deduction of issue costs. In addition, the company strengthens its shareholder base with a long-term and international investor, Eiffel Investment Group, to which the issue is directed.
Corline Biomedical develops and sells medical technology solutions. The company's shares are listed on Nasdaq First North Growth Market.
Lindahl's team consists of Mattias Prage and Olle Swärd Brattström.
Do you want to know more? Contact:
Mattias Prage
Partner | AdvokatOlle Swärd Brattström
AssociateCarousel items
-
Knowledge
3/16/2026
New system for coordinated register checks in public procurement
The Government has proposed a new system for coordinated register checks in public procurement, with a proposed entry into force on 1 July 2026.
-
Cases and transactions
3/11/2026
Lindahl advises Jajum AB and OssAv AB on the sale of Amplius Omsorg AB
Lindahl advised Jajum AB and OssAv AB on the sale of Amplius Omsorg AB, active within residential care, sheltered housing and foster care, to Sekoya AS.
-
News articles
2/12/2026
Lindahl ranked in Chambers and Partners Global Guide 2026
Lindahl is proud to once again be ranked in Chambers and Partners Global Guide. This year's ranking confirms the firm's strong position within several business-critical practice areas.
-
Portraits
1/20/2026
How I use AI in my daily work as a lawyer
AI is no longer the future – it is everyday reality. Johanna Karlsson, lawyer and senior associate at Lindahl, talks about how AI tools such as Legora have become a natural part of her workflow.
-
Read more news and insights?
